Education
About Us
Working with TipRanks
Follow Us
American Shared Hospital Services (AMS)
:AMS
RESEARCH TOOLSreports
Top Page
American Shared Hospital Services
(NYSE MKT:AMS)
65Neutral
American Shared Hospital Services (AMS) vs. S&P 500 (SPY)
Market Cap
$17.85M
Dividend YieldN/A
Average Volume (3M)21.48K
Price to Earnings (P/E)4.8
Beta (1Y)0.37
Revenue Growth20.83%
EPS Growth765.57%
CountryUS
Employees31
SectorHealthcare
Sector Strength65
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.60
Shares Outstanding6,420,000
10 Day Avg. Volume5,642
30 Day Avg. Volume21,481
Financial Highlights & Ratios
PEG Ratio0.00624
Price to Book (P/B)N/A
Price to Sales (P/S)0.72
Price to Cash Flow (P/CF)9.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
American Shared Hospital Services Business Overview & Revenue Model
Company DescriptionAmerican Shared Hospital Services (AMS) is a healthcare services company that provides turnkey technology solutions for advanced medical treatments to hospitals and medical centers. The company specializes in leasing radiosurgery and radiation therapy equipment, including Gamma Knife and proton beam therapy systems, primarily focused on oncology and neurosurgery sectors. AMS plays a critical role in facilitating access to cutting-edge medical technologies for healthcare facilities that may not have the resources to independently acquire such equipment.
How the Company Makes MoneyAMS generates revenue through leasing arrangements with hospitals and medical centers for their high-cost, advanced medical equipment. The company provides facilities with access to state-of-the-art radiosurgery and radiation therapy equipment, such as the Gamma Knife and proton beam therapy systems, on a fee-per-use or long-term lease basis. This model allows AMS to earn consistent income from leasing fees while enabling healthcare institutions to offer advanced treatment options without the burden of significant capital expenditures. Additionally, AMS may engage in partnerships with equipment manufacturers and healthcare providers, further enhancing its service offerings and revenue potential.
American Shared Hospital Services Financial Statement Overview
Summary
American Shared Hospital Services demonstrates strong revenue growth and improved profitability, which are key strengths. The balance sheet remains robust with a solid equity position and reasonable leverage. However, cash flow challenges, particularly in operating cash flow, pose a potential risk. Overall, the financial health of the company is stable, with opportunities for enhancing operational efficiency and cash flow management.Income Statement
American Shared Hospital Services has shown a positive revenue growth trend with a significant increase in total revenue from $21.3M in 2023 to $24.9M in TTM 2024, marking a growth rate of 17.1%. The gross profit margin for TTM 2024 is strong at 34.8%, although slightly down from the previous year. Net profit margin has improved considerably to 15.7% in TTM 2024 from 2.9% in 2023, indicating enhanced profitability. However, the EBIT margin is relatively low at 4.0%, suggesting that operational efficiency could be improved.78
Positive
Balance Sheet
The company's balance sheet reflects a solid equity base with an equity ratio of 41.8% in TTM 2024, indicating a stable financial structure. The debt-to-equity ratio is 0.91, showing a balanced use of debt financing. However, the return on equity is moderate at 14.9%, suggesting room for improvement in generating returns for shareholders. Overall, the company maintains a healthy balance sheet with manageable leverage levels.72
Positive
Cash Flow
Cash flow performance is mixed, with a negative free cash flow of $6.5M in TTM 2024, primarily due to negative operating cash flow. The operating cash flow to net income ratio is negative, indicating cash flow challenges despite reported net income. Although there has been significant cash flow from financing activities, it remains crucial for the company to improve its operating cash flow generation.65
Positive
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 24.97M | 21.32M | 19.75M | 17.63M | 17.84M | 20.61M | Gross Profit |
| 8.69M | 9.34M | 8.38M | 6.73M | 4.47M | 6.92M | EBIT |
| 1.00M | 270.00K | -1.46M | -2.78M | -132.00K | -4.54M | EBITDA |
| 11.01M | 6.97M | 8.44M | 6.97M | -1.14M | 10.27M | Net Income Common Stockholders |
| 3.93M | 610.00K | 1.33M | 678.00K | -7.72M | 1.43M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 552.00K | 13.69M | 12.45M | 8.26M | 3.96M | 1.78M | Total Assets |
| 62.23M | 48.16M | 43.96M | 45.43M | 43.65M | 53.78M | Total Debt |
| 35.41M | 15.68M | 14.31M | 16.13M | 14.40M | 16.95M | Net Debt |
| 34.85M | 1.87M | 1.86M | 7.87M | 10.44M | 15.17M | Total Liabilities |
| 39.36M | 21.88M | 22.33M | 21.19M | 20.00M | 21.97M | Stockholders Equity |
| 22.86M | 22.62M | 21.63M | 24.24M | 19.27M | 31.81M |
| Cash Flow | Free Cash Flow | ||||
| -6.53M | -555.00K | 6.85M | 4.59M | 9.29M | 7.06M | Operating Cash Flow |
| -3.16M | 5.72M | 7.24M | 6.27M | 9.74M | 8.05M | Investing Cash Flow |
| -2.80M | -6.27M | -388.00K | -1.67M | -2.39M | -990.00K | Financing Cash Flow |
| 5.38M | 1.91M | -2.66M | -655.00K | -4.81M | -7.07M |
American Shared Hospital Services Technical Analysis
Neutral
2.85
Price Trends
2.94
Negative
3.07
Negative
3.10
Negative
Market Momentum
-0.03
Negative
43.61
Neutral
44.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMS, the sentiment is Neutral. The current price of 2.85 is above the 20-day moving average (MA) of 2.80, below the 50-day MA of 2.94, and below the 200-day MA of 3.10, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 43.61 is Neutral, neither overbought nor oversold. The STOCH value of 44.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AMS.
American Shared Hospital Services Risk Analysis
American Shared Hospital Services disclosed 20 risk factors in its most recent earnings report. American Shared Hospital Services reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
American Shared Hospital Services Peers Comparison
Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $17.85M | 4.78 | 16.19% | ― | 20.83% | 765.57% | |
55 Neutral | $1.95B | 278.74 | 0.90% | 10.31% | -17.69% | -99.09% | |
54 Neutral | $477.92M | ― | -8.57% | ― | -6.49% | -205.13% | |
52 Neutral | $252.08M | 25.27 | -4.64% | ― | -54.17% | -135.78% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
46 Neutral | $2.97B | ― | -34.77% | 4.28% | -4.34% | -634.89% |
* Healthcare Sector Average
Performance Comparison
AMS
American Shared Hospital Services
2.85
-0.07
-2.40%
CVI
CVR Energy
19.22
-17.06
-47.02%
XRAY
DENTSPLY SIRONA
14.65
-16.23
-52.56%
OSUR
Orasure Technologies
3.32
-2.86
-46.28%
VREX
Varex Imaging
11.43
-6.58
-36.54%
American Shared Hospital Services Earnings Call Summary
Earnings Call Date: Nov 13, 2024 | % Change Since: -11.21% | Next Earnings Date: Apr 4, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a mix of strong revenue growth and significant strategic expansions with the Rhode Island acquisition and international developments, countered by challenges in the Gamma Knife segment and increased operational costs leading to a net loss.Highlights
Strong Revenue Growth
Third quarter revenue increased by 36.3% to $6.99 million compared to $5.13 million in the previous year, driven by the Rhode Island acquisition and the new facility in Puebla, Mexico.
Retail Segment Expansion
Revenue from the company's Retail segment increased by 273% year-over-year. This growth was largely due to the acquisition of Rhode Island companies and the startup of operations in Puebla.
International Business Growth
AMS expanded its international presence with the opening of a facility in Puebla, Mexico, and plans for a new Gamma Knife facility in Guadalajara, Mexico.
Rhode Island Acquisition Benefits
The Rhode Island acquisition added significant value, with $8 million in net assets acquired for $3 million, including $2.4 million in cash.
Lowlights
Gamma Knife Volume Decline
Total Gamma Knife revenue decreased by 32.9% due to the expiration of a contract, equipment downtime, and staffing shortages.
Increased Operating Loss
The company reported an operating loss of $889,000, largely due to increased costs from the Rhode Island acquisition and lower Gamma Knife volumes.
Lower Gross Margin
Gross margin decreased to $1.37 million from $2.10 million in the previous year, impacted by lower Gamma Knife treatment volumes and growth in the lower-margin Retail segment.
Net Loss Reported
AMS reported a net loss of $207,000 or $0.03 per share, compared to a net income of $118,000 or $0.02 per share in the previous year.
Company Guidance
During the AMS Q3 2024 earnings call, the company reported a 36% year-over-year revenue growth, reaching $6.99 million, bolstered by the Rhode Island acquisition and the new Puebla, Mexico facility. Despite this growth, the company faced challenges such as a decline in gross margin by $732,000, attributed to reduced Gamma Knife treatment volumes and a shift in revenue mix towards its Retail segment. The net loss for the quarter was $207,000, or $0.03 per share, compared to a gain of $118,000, or $0.02 per share, in Q3 2023. Cash and equivalents were strong at $14.1 million, with $4.5 million outstanding on a $7 million line of credit. The call emphasized strategic expansions and investments, including a 273% increase in Retail segment revenue, although the company acknowledged the impact of temporary start-up costs and operational inefficiencies from recent acquisitions. Adjusted EBITDA was reported at $1.37 million, down from $1.67 million in the previous year.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.